EBNEO Commentary: Efficacy and safety of enteral recombinant human insulin in preterm infants: A randomised clinical trial
- PMID: 35841282
- DOI: 10.1111/apa.16479
EBNEO Commentary: Efficacy and safety of enteral recombinant human insulin in preterm infants: A randomised clinical trial
Comment on
-
Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial.JAMA Pediatr. 2022 May 1;176(5):452-460. doi: 10.1001/jamapediatrics.2022.0020. JAMA Pediatr. 2022. PMID: 35226099 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database Syst Rev. 2020;10(10):Cd005496.
-
- Ng E, Shah VS. Erythromycin for the prevention and treatment of feeding intolerance in preterm infants. Cochrane Database Syst Rev. 2008;3(3):CD001815.
-
- Tan-Dy CR, Ohlsson A. Lactase treated feeds to promote growth and feeding tolerance in preterm infants. Cochrane Database Syst Rev. 2005;2(2):CD004591.
-
- Kohl M, Wuerdemann I, Clemen J, Iven H, Katalinic A, Moeller JC. Cisapride may improve feeding tolerance of preterm infants: a randomized placebo-controlled trial. Biol Neonate. 2005;88(4):270-275.
-
- Schoenfeld DA. Pro/con clinical debate: it is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: futility stopping can speed up the development of effective treatments. Crit Care. 2005;9(1):34-36.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical